Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, 1 mg/day finasteride lowered serum PSA concentration in men aged 40–60, suggesting that PSA adjustment recommendations for prostate cancer screening using 5 mg/day finasteride should also apply to this lower dose for hair loss treatment.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This article discusses the role of dihydrotestosterone in human prostatic adenocarcinoma growth and suggests that 6-methyleneprogesterone could be used to inhibit DHT for treating hormone-responsive prostate cancer, without new clinical findings.

This study suggests that a larger prostate is associated with a higher prevalence of androgenetic alopecia, although the prostate size did not correlate with alopecia severity.

This article reviews advancements in hair restoration, highlighting improvements in surgical techniques and patient satisfaction, but reports no new clinical results.

This study found that androgenic alopecia at an early age was associated with a lower risk of prostate cancer, contrary to assumptions about androgens' role.

This review discusses the hormonal influences on prostate carcinogenesis and notes ongoing trials investigating whether finasteride could reduce prostate cancer incidence by inhibiting dihydrotestosterone synthesis, but it reports no new results.

This article reviews recent advancements in understanding hair follicle biology, with a focus on the potential for gene therapy in treating alopecia, but it reports no new research findings.

This study found that Monascus cursory extraction reduced baldness, prostate hyperplasia, and tumor incidence in animal models of androgen-related diseases, suggesting it may be a promising new therapeutic candidate.

This review discusses the expression of PSA in hormonally-regulated tissues and female malignancies, emphasizing its potential as a diagnostic biomarker and role in antidoping initiatives.

This review covers recent advances in prostate cancer risk assessment, diagnosis, and treatment but does not report new clinical results; further studies on androgen deprivation therapy's cardiovascular risks are particularly noted.

In this study, researchers developed a new prostate cancer imaging agent, a [99m Tc]tricarbonyl complex derived from finasteride, which demonstrated high radiochemical purity and significant uptake in the prostate of a rat model, suggesting its potential for noninvasive prostate cancer imaging.

This review highlights that while bariatric surgery is effective for weight loss and health improvement, it also presents significant postoperative physical and psychological challenges, emphasizing the need for holistic care to ensure long-term success in treating obesity.

This study examined the most common chemotherapy side effects among patients with prostate, bladder, and testicular cancer, noting hair loss, fatigue, and decreased appetite as frequent symptoms.

This letter to the editor references a study on using dihydrotestosterone gel before hypospadias surgery but itself contains no new findings.

This review discusses the causes and understanding of telogen effluvium, a form of hair loss following physiological stress, and provides no new clinical findings.

This study reports that Abelson Interactor 1 (ABI1) regulates androgen receptor transcription in prostate cancer, identifying it as a potential target for new therapies addressing treatment resistance.

This study found that aqueous extract of Pueraria mirifica, when administered to a rat model, significantly reduced prostate weight, prostatic index, and serum dihydrotestosterone levels, while also improving prostate histomorphology, suggesting its potential as an anti-BPH treatment.

This study suggests that extracellular vesicles from prostate cancer cells could aid in identifying tumor heterogeneity and serve as biomarkers, while also playing a role in SARS-CoV-2 infection in nasopharyngeal mucus.

This review suggests that finasteride at 1 mg/day reduces PSA levels similarly to 5 mg/day, but differences in prostate dihydrotestosterone levels may affect prostate cancer diagnosis and prevention.

Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.

This review discusses significant developments in prostate cancer risk assessment, diagnosis, and treatment, but reports no new clinical results; the authors emphasize the evolving importance of prognostic factors and treatment implications.

This study found that taking 1 mg of finasteride daily for male-pattern hair loss significantly reduces serum PSA levels, suggesting similar PSA adjustment is needed as for higher doses during prostate cancer screening.

The book details advanced techniques in cosmetic dermatology for experienced surgeons.

The abstract reports no new results but discusses Berry's belief that most changes in breast cancer incidence are due to screening, measurement adjustments, or hormone use.

This study found that the AR-E211 A allele is associated with a lower risk of both metastatic prostate cancer and androgenetic alopecia in an Australian population.

This article discusses the challenges and possible solutions in hair restoration surgery, focusing on donor hair availability, hair survival, and concealing surgical evidence, and reports no new clinical results.

This study observed that frontal plus moderate vertex baldness at age 45 was associated with a higher risk of aggressive prostate cancer in a large cohort.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This review discusses gender identity disorder in Japan, highlighting the high prevalence and challenges in accessing appropriate treatment, and calls for wider understanding among medical professionals.